Court cuts Samsung BioLogics a break during probe of its accounting for Biogen deal

Samsung BioLogics South Korea
Before being embroiled in an accounting scandal, Samsung BioLogics' rapid production expansion was powering revenues. (Samsung BioLogics)

A South Korean court has hit pause on the penalties imposed by the country’s accounting regulator against Samsung BioLogics for the way it handled accounting for a joint venture with Biogen.

The court decided the allegations of the Financial Services Commission (FSC) have yet to be proven and the regulator's actions "could lead to irreparable damage” for the Korean biologics maker, a court official told Reuters.

The company confirmed the ruling to the news service. “The court’s decision is fortunate. We will do our best to prove the legitimacy of the company’s handling of accounting,” a Samsung official said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Samsung BioLogics strikes back, filing lawsuit over criminal penalties imposed by Korean regulators

Samsung BioLogics, which has denied any wrongdoing, filed an administrative lawsuit against the FSC in November after the regulator slapped Samsung with a number of strict penalties for allegedly violating accounting rules. The agency imposed a $7 million fine, recommended the firing of BioLogics’ chief executive Kim Tae-han and referred the case to criminal prosecutors. It also suspended trading in the company’s stock, but that resumed in December after the exchange ruled that the company’s shares could remain listed while the case played out.

The review centered around a 2015 financial report in which Samsung BioLogics reported that it had swung from years of losses to a sudden profit. That happened after it changed the method by which it valued the JV, Samsung Bioepis. Regulators alleged the change was not only a violation of accounting rules but also an improper method for inflating the company's net profit before going public.

Samsung BioLogics, an affiliate of tech giant Samsung Electronics, has said that the change in valuation method was approved by KPMG Korea, Deloitte Korea and PricewaterhouseCoopers Korea. The FSC also punished those auditors, fining KPMG and barring it from auditing the company for five years, and banning Deloitte from working for the company for three years.

RELATED: Biogen to spend $700M to build its stake to 49.9% in biosims joint venture with Samsung

The legal imbroglio has not deterred Biogen, which last summer upped its stake in the JV to 49% with a $700 million investment. Prior to the FSC action, Samsung BioLogics was on a rapid upward trajectory. Its 2017 sales grew by 56% year over year to $420 million, thanks to expanding production volume at its manufacturing facilities. In August, Samsung included its biopharma operations in its plans to invest $22 billion in high-growth business lines.

The matter is now in the hands of prosecutors, which raided the headquarters of Samsung Biologics in December.

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.